Quercetin Administration in Adult Patients as a Biochemical Potential against Coronavirus Disease 2019 (COVID-19)

Quercetin Administration in Adult Patients as a Biochemical Potential against Coronavirus Disease 2019 (COVID-19)

juan_fernando_ibarra_aguilar

Contact

Juan Fernando Ibarra Aguilar

Contact

Gabriela Ariane Sanabria Báez

Contact

Fernando Galeano

Contact

Quercetin Administration in Adult Patients as a Biochemical Potential against Coronavirus Disease 2019 (COVID-19)

Article Fingerprint

ReserarchID

2J09Z

Quercetin Administration in Adult Patients as a Biochemical Potential against Coronavirus Disease 2019 (COVID-19) Banner

AI TAKEAWAY

Connecting with the Eternal Ground

References

26 Cites in Article

Reference Format

M Mrityunjaya,V Pavithra,R Neelam,P Janhavi,P Halami,P Ravindra (2020). Immune-Boosting, Antioxidant and Anti-inflammatory Food Supplements Targeting Pathogenesis of COVID-19.
Mª Linares (2020). HERRAMIENTAS DE LA COMUNIDAD INTERNACIONAL FRENTE A LA PANDEMIA POR COVID-19:.
Gupta Dhyuti,Sahooajaya Kumar,Singh Alok (2020). Ivermectin: potential candidate for the treatment of Covid 19.
J Moreira,W Lima,W Da Cruz (2021). Quercetin as a potential nutraceutic against coronavirus disease 2019 (COVID-19).
Borys Palamar,Tetiana Gruzeva (2019). THE ESTIMATION OF ECONOMIC EFFECTIVENESS OF PREVENTIVE MEASURES OF NON-INFECTIOUS DISEASES.
J Chen,D Liu,L Liu,P Liu,Q Xu,L Xia,Y Ling,D Huang,S Song,D Zhang,Z Qian,T Li,Y Shen,H Lu (2020). A pilot study of hydroxychloroquine in treatment of patients with moderate COVID-19.
Yao Li,Jiaying Yao,Chunyan Han,Jiaxin Yang,Maria Chaudhry,Shengnan Wang,Hongnan Liu,Yulong Yin (2016). Quercetin, Inflammation and Immunity.
Wenjiao Wu,Richan Li,Xianglian Li,Jian He,Shibo Jiang,Shuwen Liu,Jie Yang (2015). Quercetin as an Antiviral Agent Inhibits Influenza A Virus (IAV) Entry.
Shyamala Ganesan,Andrea Faris,Adam Comstock,Qiong Wang,Suparna Nanua,Marc Hershenson,Uma Sajjan (2012). Quercetin inhibits rhinovirus replication in vitro and in vivo.
Micholas Smith,Jeremy Smith (2020). Repurposing Therapeutics for COVID-19: Supercomputer-Based Docking to the SARS-CoV-2 Viral Spike Protein and Viral Spike Protein-Human ACE2 Interface.
Ling Yi,Zhengquan Li,Kehu Yuan,Xiuxia Qu,Jian Chen,Guangwen Wang,Hong Zhang,Hongpeng Luo,Lili Zhu,Pengfei Jiang,Lirong Chen,Yan Shen,Min Luo,Guoying Zuo,Jianhe Hu,Deliang Duan,Yuchun Nie,Xuanling Shi,Wei Wang,Yang Han,Taisheng Li,Yuqing Liu,Mingxiao Ding,Hongkui Deng,Xiaojie Xu (2004). Small Molecules Blocking the Entry of Severe Acute Respiratory Syndrome Coronavirus into Host Cells.
Ruben Colunga Biancatelli,Max Berrill,John Catravas,Paul Marik (2020). Quercetin and Vitamin C: An Experimental, Synergistic Therapy for the Prevention and Treatment of SARS-CoV-2 Related Disease (COVID-19).
Anitra Carr,Silvia Maggini (2017). Vitamin C and Immune Function.
A Furuya,Uozakim,H Yamasaki,T Arakawa,Aritakoyamamah (2008). Antiviral effects of ascorbic and dehydroascorbic acids in vitro.
Margreet Olthof,Peter Hollman,Tom Vree,Martijn Katan (2000). Bioavailabilities of Quercetin-3-Glucoside and Quercetin-4′-Glucoside Do Not Differ in Humans.
M Harwood,B Danielewska-Nikiel,J Borzelleca,G Flamm,G Williams,T Lines (2007). A critical review of the data related to the safety of quercetin and lack of evidence of in vivo toxicity, including lack of genotoxic/carcinogenic properties.
R Keller,Inc Biosciences,Assignee (2009). 5585349 Method of treating viral infections Potempa Lawrence A Deerfield, IL, United States assigned to Immtech International Inc.
Douglas Andersen,Norbert Weber,Steven Wood,Bronwyn Hughes,Byron Murray,James North (1991). In vitro virucidal activity of selected anthraquinones and anthraquinone derivatives.
Susan Semple,Simon Pyke,Geoffrey Reynolds,Robert Flower (2001). In vitro antiviral activity of the anthraquinone chrysophanic acid against poliovirus.
Ho Kim,Won Jeon,Byoung Ko (2001). Flavanone Glycosides from <i>Citrus junos</i> and their Anti-Influenza Virus Activity.
Oscar Gonzalez,Vanessa Fontanes,Santanu Raychaudhuri,Rachel Loo,Joseph Loo,Vaithilingaraja Arumugaswami,Ren Sun,Asim Dasgupta,Samuel French (2009). The heat shock protein inhibitor Quercetin attenuates hepatitis C virus production†.
Ling Yi,Zhengquan Li,Kehu Yuan,Xiuxia Qu,Jian Chen,Guangwen Wang,Hong Zhang,Hongpeng Luo,Lili Zhu,Pengfei Jiang,Lirong Chen,Yan Shen,Min Luo,Guoying Zuo,Jianhe Hu,Deliang Duan,Yuchun Nie,Xuanling Shi,Wei Wang,Yang Han,Taisheng Li,Yuqing Liu,Mingxiao Ding,Hongkui Deng,Xiaojie Xu (2004). Small Molecules Blocking the Entry of Severe Acute Respiratory Syndrome Coronavirus into Host Cells.
Christopher Booth,L Matukas,G Tomlinson,A Rachlis,D Rose,H Dwosh,S Walmsley,T Mazzulli,M Avendano,P Derkach (2003). Clinical Features and Short-term Outcomes of 144 Patients With SARS in the Greater Toronto Area.
Alaa Badawi,Seung Ryoo (2016). Prevalence of comorbidities in the Middle East respiratory syndrome coronavirus (MERS-CoV): a systematic review and meta-analysis.
Fei Zhou,Ting Yu,Ronghui Du,Guohui Fan,Ying Liu,Zhibo Liu,Jie Xiang,Yeming Wang,Bin Song,Xiaoying Gu,Lulu Guan,Yuan Wei,Hui Li,Xudong Wu,Jiuyang Xu,Shengjin Tu,Yi Zhang,Hua Chen,Bin Cao (2020). Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study.
Dawei Wang,Bo Hu,Chang Hu,Fangfang Zhu,Xing Liu,Jing Zhang,Binbin Wang,Hui Xiang,Zhenshun Cheng,Yong Xiong,Yan Zhao,Yirong Li,Xinghuan Wang,Zhiyong Peng (2020). Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus–Infected Pneumonia in Wuhan, China.

Download References

Funding

No external funding was declared for this work.

Conflict of Interest

The authors declare no conflict of interest.

Ethical Approval

No ethics committee approval was required for this article type.

Data Availability

Not applicable for this article.

How to Cite This Article

juan_fernando_ibarra_aguilar. 2021. \u201cQuercetin Administration in Adult Patients as a Biochemical Potential against Coronavirus Disease 2019 (COVID-19)\u201d. Global Journal of Medical Research - F: Diseases GJMR-F Volume 21 (GJMR Volume 21 Issue F1): .

More Citation Formats

Select Citation Style:

Download Citation

Download Article

GJMR Volume 21 Issue F1
Pg. 25- 29

Explore Journals Explore Volume Read This Issue

Journal Specifications

Crossref Journal DOI 10.17406/gjmra

Print ISSN 0975-5888

e-ISSN 2249-4618

Keywords

Not Found

Classification

GJMR-F Classification: NLMC Code: WF 140

Submission ReceivedFebruary 7, 2021
Peer Review Double Blind
Handling Editor
Accepted March 4, 2021
Published March 15, 2021

Version of record

v1.2

Issue date

March 28, 2021

Language

Experiance in AR

Explore published articles in an immersive Augmented Reality environment. Our platform converts research papers into interactive 3D books, allowing readers to view and interact with content using AR and VR compatible devices.

View in VR

Read in 3D

Your published article is automatically converted into a realistic 3D book. Flip through pages and read research papers in a more engaging and interactive format.

View in 3D

Article Matrices

Total Views: 1979

Total Downloads: 1001

2026 Trends

Published Article

Abstract not found

Our website is actively being updated, and changes may occur frequently. Please clear your browser cache if needed. For feedback or error reporting, please email [email protected]